Boston Scientific (BSX) Revenue — Quarter Ended Sep 30, 2024
Revenue increased in the current quarter compared to both the prior quarter and the same quarter last year. The growth was broad-based across all major product segments.
Key takeaway
Quarter ended Sep 30, 2024 · FY2024 Q3
Revenue increased in the current quarter compared to both the prior quarter and the same quarter last year. The growth was broad-based across all major product segments.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$4.2B
Revenue reported for this quarter.
Quarter-over-quarter
+2.2%
Change from the immediately preceding quarter.
Year-over-year
+19.3%
Change from the comparable year-ago quarter.
Trailing four quarters
$15.9B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2023 | $3.7B | +14.9% |
| Mar 31, 2024 | $3.9B | +13.8% |
| Jun 30, 2024 | $4.1B | +14.5% |
| Sep 30, 2024 | $4.2B | +19.3% |
Revenue performance
The reported revenue for the quarter reflects a sequential increase from the preceding quarter and a substantial year-over-year gain.
Quarterly comparison
Compared to the immediately preceding quarter, revenue rose, and compared to the same quarter one year earlier, revenue also rose, with the year-over-year increase being more pronounced.
What to watch
Foreign currency fluctuations had a slight negative impact on revenue growth in the Endoscopy segment, which may be worth monitoring.